CAJ | 학술논문

真菌性角膜炎居中国感染性角膜炎的首位,已成为角膜盲的主要病因.随着对发病原因及机制的深入探讨,药物治疗取得了较大进展.为降低该病的致盲率,眼科医师应重视其治疗手段并提高其治疗效果.就抗真菌药物在眼科临床应用的研究进展进行综述.
진균성각막염거중국감염성각막염적수위,이성위각막맹적주요병인.수착대발병원인급궤제적심입탐토,약물치료취득료교대진전.위강저해병적치맹솔,안과의사응중시기치료수단병제고기치료효과.취항진균약물재안과림상응용적연구진전진행종술.
Fungal keratitis is the first common infectious corneal disease and has become the main cause of blindness in China.Along with the intensive explore for the pathogenic mechanisms,the significant progress has been achieved in the pharmacotherapeutics.For lowering its blindnessrate,it is imperative to the study on increasing therapeutic option and enhancing therapeutic efficacy.This review summarizes the current advance in clinical use in ophthalmology of novel antifungal agents,including new azoles such as voriconazole and posaconazole,and echinocandins such as caspofungin and micafungin.This article also reviews the progress of administration routes for the management of recalcitrant fungal keratitis,including subconjunctival,interstromal,intracameral and intravitreal injection.